Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILIA: Tozorakimab in Hospitalised Viral Lung Infection Requiring Supplemental Oxygen
2023-507031-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in viral pneumonia comparing Tozorakimab arm with Placebo arm (2 arms). Planned start Feb 2024; status: authorised.
02
Drugs
tozorakimab
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on 2023-507031-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507031-38-00.